Diplomat Pharmacy, Inc.(DPLO): For the most recent quarter end, Diplomat Pharmacy, Inc. reported Annual Earnings of $0.21. Based on the filings, last years Annual Earnings was, $0.75. For the most recent quarter end, DPLO reported a surprise Earnings per Share of -8.7% . The consensus estimate for current quarter is $0.17 and for the current fiscal year, the estimate is $0.83. For the Next fiscal year, the estimate is $0.72 based on the consensus.
Diplomat Pharmacy, Inc. has received $0.17 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 9 Financial Advisor in the Stock Trading Firms. Among 9 Analysts, Bottom line EPS Estimate for the current quarter is $0.15 while the top line estimate is $0.18 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at -21.16%. Diplomat Pharmacy, Inc. results fell short with a surprise EPS of -8.7% or $-0.02. The Actual EPS was $0.21 compared to the Estimated EPS of $0.23 during its most recent quarterly earnings.
Diplomat Pharmacy, Inc. has a Price to Earnings ratio of 16.53 for the trailing twelve month period. The price to book ratio of the company for the most recent quarter is 1.57. For the Most Recent Fiscal Year, Diplomat Pharmacy, Inc. has a price to cash ratio of 11.87. For the Trailing twelve month period, company showed a Net Profit Margin of 0.77% and Return on Equity of the stock is 10.47%.
Diplomat Pharmacy Inc Last issued its quarterly earnings results on Nov 2, 2016. The company reported $0.21 EPS for the quarter, missing the analyst consensus estimate by $ -0.03. Analyst had a consensus of $0.24. The company had revenue of $1181.00 million for the quarter, compared to analysts expectations of $1258.11 million. The companys revenue was up 24.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.26 EPS.
Company has reported several Insider transactions to the SEC, on Sep 16, 2016, Atheer A Kaddis (EVP of Sales & Strategic Align) sold 20,000 shares at 30.12 per share price.On Dec 8, 2015, Philip R Hagerman (Chairman and CEO) sold 2,300,000 shares at 33.60 per share price.On Dec 2, 2015, Gary W Kadlec (President) sold 30,000 shares at 35.08 per share price.
Diplomat Pharmacy, Inc. (NYSE:DPLO) witnessed a decline in the market cap on Wednesday as its shares dropped 0.14% or 0.02 points. After the session commenced at $14.55, the stock reached the higher end at $14.715 while it hit a low of $14.3. With the volume soaring to 623,552 shares, the last trade was called at $14.53. The company has a 52-week high of $38.94. The company has a market cap of $970 million and there are 66,730,998 shares in outstanding. The 52-week low of the share price is $12.25.
Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. It aids in the dispensing, delivery, dosing and reimbursement of clinically intensive and specialty drugs. The company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions. Diplomat Pharmacy, Inc. is headquartered in Flint, Michigan.